Cargando…

Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

BACKGROUND: Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations. OBJECTIVE: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakazaki, Eri, Mah, Eunice, Sanoshy, Kristen, Citrolo, Danielle, Watanabe, Fumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349115/
https://www.ncbi.nlm.nih.gov/pubmed/33978188
http://dx.doi.org/10.1093/jn/nxab119
_version_ 1783735501299122176
author Nakazaki, Eri
Mah, Eunice
Sanoshy, Kristen
Citrolo, Danielle
Watanabe, Fumiko
author_facet Nakazaki, Eri
Mah, Eunice
Sanoshy, Kristen
Citrolo, Danielle
Watanabe, Fumiko
author_sort Nakazaki, Eri
collection PubMed
description BACKGROUND: Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations. OBJECTIVE: The objective of this study was to investigate the effects of citicoline (Cognizin(®)), on memory in healthy elderly populations with age-associated memory impairment (AAMI). METHODS: A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons. RESULTS: A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052). CONCLUSIONS: Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. This trial was registered at clinicaltrials.gov as NCT03369925.
format Online
Article
Text
id pubmed-8349115
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83491152021-08-09 Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Nakazaki, Eri Mah, Eunice Sanoshy, Kristen Citrolo, Danielle Watanabe, Fumiko J Nutr Nutrient Physiology, Metabolism, and Nutrient-Nutrient Interactions BACKGROUND: Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations. OBJECTIVE: The objective of this study was to investigate the effects of citicoline (Cognizin(®)), on memory in healthy elderly populations with age-associated memory impairment (AAMI). METHODS: A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons. RESULTS: A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052). CONCLUSIONS: Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. This trial was registered at clinicaltrials.gov as NCT03369925. Oxford University Press 2021-05-12 /pmc/articles/PMC8349115/ /pubmed/33978188 http://dx.doi.org/10.1093/jn/nxab119 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Nutrient Physiology, Metabolism, and Nutrient-Nutrient Interactions
Nakazaki, Eri
Mah, Eunice
Sanoshy, Kristen
Citrolo, Danielle
Watanabe, Fumiko
Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_full Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_fullStr Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_full_unstemmed Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_short Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
title_sort citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial
topic Nutrient Physiology, Metabolism, and Nutrient-Nutrient Interactions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349115/
https://www.ncbi.nlm.nih.gov/pubmed/33978188
http://dx.doi.org/10.1093/jn/nxab119
work_keys_str_mv AT nakazakieri citicolineandmemoryfunctioninhealthyolderadultsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT maheunice citicolineandmemoryfunctioninhealthyolderadultsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT sanoshykristen citicolineandmemoryfunctioninhealthyolderadultsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT citrolodanielle citicolineandmemoryfunctioninhealthyolderadultsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT watanabefumiko citicolineandmemoryfunctioninhealthyolderadultsarandomizeddoubleblindplacebocontrolledclinicaltrial